Spinal cord injury target-immunotherapy with TNF-α autoregulated and feedback-controlled human umbilical cord mesenchymal stem cell derived exosomes remodelled by CRISPR/Cas9 plasmid

Wang, Baocheng; Chang, Minmin; Zhang, Renwen; Wo, Jin; Wu, Bowen; Zhang, Hua; Zhou, Zhigang; Li, Zhizhong; Zhang, Feng; Zhong, Cheng; Tang, Shujie; Yang, Shuxian; Sun, Guodong

doi:10.1016/j.msec.2021.112624

Cited by 17 publications

(11 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The severe, destructive, and persistent inflammatory response after spinal cord injury can exacerbate local tissue damage and lead to the development of syringomyelia, characterized by the infiltration of phagocytic macrophages at the injury site. In recent years, there has been a growing emphasis on understanding the immune microenvironment after spinal cord injury, leading to the exploration of various immunotherapeutic approaches for spinal cord injury repair, demonstrating promising therapeutic prospects [ [24] , [25] , [26] ]. The efficacy of therapeutic interventions for spinal cord injury (SCI) often fall below expectations, primarily due to factors such as the diverse immune microenvironment following SCI, among others.…”

Section: Discussionmentioning

confidence: 99%

Development and validation of a differentiation-related signature based on single-cell RNA sequencing data of immune cells in spinal cord injury

Shang,

Ma,

Ding

et al. 2023

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Development and validation of a differentiation-related signature based on single-cell RNA sequencing data of immune cells in spinal cord injury

Shang,

Ma,

Ding

et al. 2023

Heliyon

View full text Add to dashboard Cite

“…On the other hand, EVs derived from various sources can be useful for treating SCI. EVs exert their effects through enhancing cell communication, promoting regeneration, and reducing inflammation in injured tissues, which inherited from the parent cells [107,[120][121][122][123][124][125][126]. The source of EVs should be carefully considered before clinical applications as it may have an impact on their therapeutic efficacy.…”

Section: Cluster 2: "Bioactive Components Of Evs"mentioning

confidence: 99%

A swift expanding trend of extracellular vesicles in spinal cord injury research: a bibliometric analysis

Zhiguo,

Ji,

Shenyuan

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

Extracellular vesicles (EVs) in the field of spinal cord injury (SCI) have garnered significant attention for their potential applications in diagnosis and therapy. However, no bibliometric assessment has been conducted to evaluate the scientific progress in this area. A search of articles in Web of Science (WoS) from January 1, 1991, to May 1, 2023, yielded 359 papers that were analyzed using various online analysis tools. These articles have been cited 10,842 times with 30.2 times per paper. The number of publications experienced explosive growth starting in 2015. China and the United States led this research initiative. Keywords were divided into 3 clusters, including “Pathophysiology of SCI”, “Bioactive components of EVs”, and “Therapeutic effects of EVs in SCI”. By integrating the average appearing year (AAY) of keywords in VoSviewer with the time zone map of the Citation Explosion in CiteSpace, the focal point of research has undergone a transformative shift. The emphasis has moved away from pathophysiological factors such as “axon”, “vesicle”, and “glial cell” to more mechanistic and applied domains such as “activation”, “pathways”, “hydrogels” and “therapy”. In conclusions, institutions are expected to allocate more resources towards EVs-loaded hydrogel therapy and the utilization of innovative materials for injury mitigation.

show abstract

“…Zhuang et al fused tetrahedral DNA nanostructures (TDNs) with cancer protein-specific DNA aptamers and cholesterols for anchoring to the EV membrane using a modified heat-shock process, which resulted in reduced tumour size due to gene editing, however increased liver toxicity (Zhuang et al, 2020). Wang et al chemically crosslinked a CAQK peptide to the EV membrane which increased accumulation at the spinal cord injury (SCI) site (Wang et al, 2022).…”

Section:  Targeting Evs To Specific Cells and Tissuesmentioning

confidence: 99%

CRISPR delivery with extracellular vesicles: Promises and challenges

Berggreen,

Petersen,

Lin

et al. 2023

J of Extracellular Bio

View full text Add to dashboard Cite

The CRISPR gene editing tool holds great potential for curing genetic disorders. However, the safe, efficient, and specific delivery of the CRISPR/Cas9 components into cells and tissues remains a challenge. While many currently available delivery methods achieve high levels of gene editing effects in vivo, they often result in genotoxicity and immunogenicity. Extracellular vesicles (EVs), which are cell‐derived lipid nanoparticles, are capable of transferring protein and nucleic acid cargoes between cells, making them a promising endogenous alternative to synthetic delivery methods. This review provides a comprehensive analysis of the currently available strategies for EV‐mediated delivery of CRISPR/Cas9. These strategies include cell‐based, passive loading obtained by overexpression of CRISPR/Cas9, active loading involving protein or RNA dimerization, and loading into already purified EVs. All these approaches suggest that EV‐based CRISPR/Cas9 delivery is useful for achieving both in vitro and in vivo gene editing. Despite that, substantial variations in cellular uptake and gene editing efficiencies indicate that further improvement and standardization are required for the therapeutic use of EVs as a CRISPR/Cas9 delivery vehicle. These improvements include, but is not limited to, the high‐yield purification of EVs, increased loading and release efficiencies, as well as improved tissue‐ or cell‐specific targeting specificities.

show abstract

Spinal cord injury target-immunotherapy with TNF-α autoregulated and feedback-controlled human umbilical cord mesenchymal stem cell derived exosomes remodelled by CRISPR/Cas9 plasmid

Cited by 17 publications

References 44 publications

Development and validation of a differentiation-related signature based on single-cell RNA sequencing data of immune cells in spinal cord injury

Development and validation of a differentiation-related signature based on single-cell RNA sequencing data of immune cells in spinal cord injury

A swift expanding trend of extracellular vesicles in spinal cord injury research: a bibliometric analysis

CRISPR delivery with extracellular vesicles: Promises and challenges

Contact Info

Product

Resources

About